AABB seeks comments on form to streamline transfusion adverse reaction reporting

Create PDF

January 2018—The AABB is seeking comments by March 30 on its common transfusion reaction reporting form, the seven pages of which are presented online at www.bit.ly/AABB-reportform. The fillable PDF form is intended to be used by hospitals and blood centers to communicate information about transfusion reactions to the blood supplier, particularly when there are multiple suppliers to the hospital transfusion service.

The form is designed to streamline the process for hospitals and provide blood suppliers with complete information so they can investigate the transfusion reactions. The form collects data about transfusion reactions that are suspected to be the result of an attribute specific to the donor or to the processing of the blood product transfused. They include transfusion-associated acute lung injury, septic transfusion reactions, and allergic/anaphylactic reactions. Questions are intended to assist the blood center(s) in further investigating transfusion reactions. The form captures component identification information for all components transfused to the patient.

A single form, accepted by all blood suppliers, can reduce the reporting burden for hospital transfusion services. The form allows blood centers to import transfusion reaction data into local systems or spreadsheets. The definitions used for reported adverse reactions are consistent with those in the Centers for Disease Control and Prevention’s National Healthcare Safety Network Hemovigilance Module protocol.

The AABB patient safety organization advisory committee and the donor hemovigilance working group collaborated to develop the form. These groups, which represent hospital transfusion services and blood collecting organizations, respectively, reviewed proprietary forms from a number of large blood centers and developed the harmonized form for hospital and blood center use.

[hr]

Send your comments to Hemovigilance@aabb.org with the subject line “Common transfusion reaction reporting form,” by close of business on March 30.